$52.3 B

SHPG Mkt cap, 16-Aug-2018

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Shire Income Statement

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.5 m4.7 m14.1 m18.2 m26.5 m19.2 m20.1 m29 m32.4 m119.6 m108 m98.3 m114 m111.4 m103.4 m109.3 m120.6 m122.3 m67.1 m58.2 m47.6 m15.2 b

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)9467%70%39%

Cost of goods sold

4.7 b

Gross profit

10.5 b

Gross profit Margin, %

69%

R&D expense

1.8 b

General and administrative expense

3.5 b

Operating expense total

6 m6.5 m13.9 m20.4 m27.2 m32.6 m36.3 m39.1 m41.8 m101.5 m159.8 m95.1 m100.7 m104.7 m106.5 m113.1 m120.3 m123.2 m70.1 m55.9 m46.4 m5.3 b

Depreciation and amortization

1.2 b1.8 b

EBITDA

32.9 m40.9 m34.4 m(1.1 m)(1.5 m)3 m1.7 m(433 k)3.7 m1.8 m

EBITDA margin, %

33%36%31%(1%)(1%)2%1%(1%)6%4%

EBIT

(526.4 k)(1.9 m)175 k(2.2 m)(735 k)(13.3 m)(16.1 m)(10.1 m)(9.4 m)18.2 m(51.8 m)3.3 m13.3 m6.7 m(3.1 m)(3.9 m)354 k(905 k)(3.1 m)2.3 m1.1 m2.5 b

EBIT margin, %

(10%)(40%)1%(12%)(3%)(69%)(80%)(35%)(29%)15%(48%)3%12%6%(3%)(4%)0%(1%)(5%)4%2%16%

Interest expense

578.9 m

Interest income

9.7 m

Pre tax profit

(939.6 k)(1.9 m)1.2 m(762 k)(179 k)(11.8 m)(14 m)(10.7 m)(10.5 m)22.3 m(54.2 m)5.1 m15.8 m7.1 m(2.9 m)(3.2 m)1.3 m626 k(5.7 m)5.6 m2.4 m1.9 b

Income tax expense

(404 k)4.2 m(4.4 m)(16.6 m)(11.3 m)2.4 m(691 k)(2.4 m)990 k503 k303 k947 k2.9 m(2.6 m)28 k2.4 b

Net Income

(939.6 k)(1.9 m)1.2 m(762 k)(179 k)(12.2 m)(9.8 m)(15.1 m)(10.5 m)5.7 m(65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m2.5 m4.3 b

Shire Balance Sheet

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.7 k219.3 k17 k4 k135.5 m528.8 m472.4 m

Accounts Receivable

5 k4 k1.2 b2.6 b3 b

Prepaid Expenses

197.4 m806.3 m795.3 m

Inventories

455.3 m544.8 m635.4 m3.6 b3.3 b

Current Assets

6.1 m7.4 m22.4 m16 m21 m41.2 m21.4 m5.9 m7.4 m72.4 m51.1 m75.3 m116.7 m143.6 m148.2 m145.6 m148.6 m156.6 m151.6 m158.9 m7.5 b7.6 b

PP&E

205.5 k188 k432 k507 k12.1 m12.3 m12.7 m20.7 m19.5 m21.3 m23.3 m22.9 m26.9 m38.8 m37.4 m40.7 m38.7 m37 m8.4 m7 m6.5 b6.6 b

Goodwill

225 k166 k4.1 b17.9 b19.8 b

Total Assets

6.4 m7.6 m22.8 m16.5 m33.1 m53.5 m34.1 m26.6 m26.9 m273.3 m158.9 m151.2 m170.4 m182.9 m186 m186.7 m187.6 m193.9 m178.7 m181.9 m67 b67.8 b

Accounts Payable

398.1 k533.1 k486 k1 m2 m594 k673 k88 k1.3 m1.9 m730 k356 k2.9 m295 k4.6 m2.5 m3.3 m1.8 m424 k486 k4.3 b4.2 b

Short-term debt

1.5 b3.1 b2.8 b

Current Liabilities

1.5 m4.6 m15.9 m10.3 m27.1 m59.2 m49.6 m57.2 m67.9 m81.1 m32.1 m14.4 m15.7 m18.3 m21.6 m22 m20.4 m23.6 m13 m12.1 m7.7 b7.9 b

Long-term debt

69.9 m19.9 b16.8 b

Non-Current Liabilities

227.5 m226.7 m227.2 m3.6 m6.6 m5.5 m5.5 m4.3 m3.4 m292 k113 k30.3 b23.7 b

Total Debt

278 k1.2 m2.9 m4.8 m4.9 m2.9 m540 k56 k124 k1.6 b19.9 b19.5 b

Total Liabilities

1.5 m4.6 m15.9 m10.3 m27.1 m59.2 m49.6 m57.2 m67.9 m308.6 m258.8 m241.6 m19.3 m24.9 m27 m27.5 m24.6 m26.9 m13.2 m12.2 m38.1 b31.6 b

Common Stock

58.9 m81.3 m81.6 m

Additional Paid-in Capital

6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m6.1 m230.6 m230.6 m230.6 m230.6 m230.6 m230.6 m230.6 m230.6 m24.7 b25.1 b

Retained Earnings

(939.6 k)(1.9 m)1.2 m(762 k)(179 k)(12.2 m)(9.8 m)(15.1 m)(10.5 m)5.7 m(65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m5.9 b9.9 b

Total Equity

4.9 m3 m6.9 m6.2 m6 m(5.7 m)(15.5 m)(30.5 m)(41.1 m)(35.3 m)(99.9 m)(90.4 m)151.1 m157.9 m159 m159.2 m163 m167 m165.4 m169.8 m28.9 b36.2 b

Debt to Equity Ratio

0.1 x0.2 x0.5 x0.8 x-0.9 x-0.2 x0 x0 x0 x9.3 x0.7 x0.5 x

Debt to Assets Ratio

0 x0.1 x0.2 x0.1 x0.1 x0.1 x0 x0 x0 x8.7 x0.3 x0.3 x

Financial Leverage

1.3 x2.5 x3.3 x2.7 x5.5 x-9.4 x-2.2 x-0.9 x-0.7 x-7.7 x-1.6 x-1.7 x1.1 x1.2 x1.2 x1.2 x1.2 x1.2 x1.1 x1.1 x2.3 x1.9 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

74.3 m64 m44.9 m69 m693.4 m728.6 m369 m263.7 m209.3 m

Accounts Receivable

1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b2.8 b2.8 b

Prepaid Expenses

216.6 m221.6 m215 m314.4 m733.6 m665.3 m787.2 m778.5 m779.9 m

Inventories

588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b3.3 b3.4 b

Current Assets

2.5 b2.5 b2.7 b2.4 b9.7 b8.9 b7.1 b7.2 b7.3 b7.9 b

PP&E

821.9 m816.7 m795.9 m837.6 m6.6 b6.5 b6.5 b6.6 b6.6 b

Goodwill

4.2 b4.2 b4.3 b6.9 b13 b14.9 b19.1 b19.5 b19.7 b

Total Assets

17.7 b17 b17.5 b24.1 b70.7 b69.8 b66.2 b67.2 b67.5 b

Accounts Payable

2 b1.9 b2 b2 b3.7 b4 b3.6 b3.8 b3.9 b3.9 b

Short-term debt

2.6 b2.2 b2 b2.2 b2.7 b2.7 b3 b3.2 b2.6 b

Current Liabilities

4.9 b4.3 b4.3 b4.3 b6.9 b7.1 b7 b7.4 b7.5 b

Long-term debt

78.7 m73.9 m70.7 m4.7 b21.3 b21 b19.5 b18.4 b18 b

Non-Current Liabilities

3.8 b3.6 b3.6 b9.4 b34.1 b32.9 b29.4 b2.8 b27.4 b

Total Debt

2.6 b2.3 b2.1 b6.9 b24 b23.7 b22.5 b21.6 b20.6 b

Total Liabilities

8.7 b7.9 b7.9 b13.8 b41 b40 b36.4 b35.9 b34.8 b

Common Stock

58.9 m58.9 m58.9 m59 m81 m81.3 m81.4 m81.5 m81.5 m

Additional Paid-in Capital

4.4 b4.4 b4.4 b4.5 b24.5 b24.6 b24.9 b25 b25 b

Retained Earnings

5 b5.1 b5.5 b6.2 b5.9 b5.5 b6.3 b6.3 b6.9 b

Total Equity

9 b9.1 b9.6 b10.3 b29.8 b29.8 b29.7 b31.3 b32.7 b37.4 b

Debt to Equity Ratio

0.3 x0.3 x0.2 x0.7 x0.8 x0.8 x0.8 x0.7 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x

Financial Leverage

2 x1.9 x1.8 x2.3 x2.4 x2.3 x2.2 x2.1 x2.1 x

Shire Cash Flow

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6 k)(1.9 m)1.2 m(762 k)(179 k)(12.2 m)(9.8 m)(15.1 m)(10.5 m)5.7 m(65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m2.5 m4.3 b

Depreciation and Amortization

324.4 m407.3 m637.2 m1.5 b2.3 b

Accounts Receivable

(211.4 m)(701.7 m)(487.6 m)

Inventories

(63.2 m)(255.8 m)(145.1 m)

Accounts Payable

109.2 m621.6 m(526.8 m)

Cash From Operating Activities

2.3 b2.7 b4.3 b

Purchases of PP&E

(157 m)(114.7 m)(648.7 m)(798.8 m)

Cash From Investing Activities

(360.9 m)(4 b)(5.6 b)(18.1 b)(700.9 m)

Short-term Borrowings

(3.1 b)(16.4 b)(7.7 b)

Dividends Paid

(134.4 m)(171.3 m)(281.3 m)

Cash From Financing Activities

439 m15.8 b(3.6 b)

Net Change in Cash

(2.8 b)393.3 m(56.4 m)

Interest Paid

(29.9 m)(14.5 m)(20 m)(284 m)554.2 m

Income Taxes Paid

947 k2.9 m(145.9 m)(431 m)524.7 m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4 m570 m1 b419 m256.9 m(129.9 m)375 m615.3 m1.2 b

Depreciation and Amortization

120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m1 b1.6 b

Accounts Receivable

(85.1 m)(84.9 m)(288.1 m)(100.9 m)(181 m)(411.2 m)(35.3 m)(181.5 m)(301.5 m)

Inventories

(22 m)(37.4 m)(21.7 m)(32.2 m)(116.4 m)(228 m)(151.8 m)(171.6 m)(245.2 m)

Accounts Payable

77.5 m(39.8 m)56.5 m(154.6 m)342.7 m315.2 m(671.5 m)(445.1 m)(557.8 m)

Cash From Operating Activities

561.6 m1 b1.6 b389.5 m980.4 m1.5 b459.1 m1.7 b2.7 b

Purchases of PP&E

(22.3 m)(39.8 m)(62.1 m)(51.6 m)(179.1 m)(402.5 m)(212.5 m)(391.1 m)(565.5 m)

Cash From Investing Activities

(5.2 b)(5.2 b)(5.6 b)(5.7 b)(17.6 b)(17.8 b)(219.8 m)(355.9 m)(491.2 m)

Short-term Borrowings

(535.2 m)(1.5 b)(2.5 b)(995.1 m)(1.5 b)(14.6 b)(1.8 b)(3.5 b)(5.7 b)

Dividends Paid

(110.2 m)(110.2 m)(130.2 m)(130.2 m)(234.7 m)(234.7 m)

Cash From Financing Activities

1.7 b1.3 b1.1 b5.2 b17.2 b16.9 b(401.8 m)(1.6 b)(2.6 b)

Net Change in Cash

(2.9 b)(2.9 b)(2.9 b)(66.5 m)557.9 m593.1 m(159.8 m)(265.1 m)(319.5 m)

Interest Paid

(5 m)(9.9 m)(13.1 m)(13.9 m)(111.4 m)223.4 m108.2 m267 m434.9 m

Income Taxes Paid

48.8 m(65.2 m)(97.5 m)(89.6 m)(253.7 m)355.8 m23.1 m176 m308 m
Report incorrect company information

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7

Projects in R&D Pipeline

27 29 37 40

Countries

68 72 100 100

Preclinical Phase Products

33 33 35 35

Franchises

7

Manufacturing Sites

14

New Product Launches

50

Products Marketed

40
Report incorrect company information

Shire Human Capital

Shire's employees are reported to be approximately 52% female and 48% male.

Gender

FY, 2016FY, 2015
Male48 %50 %
Female52 %50 %
Report incorrect company information